Golcadomide FDA Approval Status
Last updated by Judith Stewart, BPharm on July 2, 2025.
FDA Approved: No
Generic name: golcadomide
Company: Bristol-Myers Squibb Company
Treatment for: Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Golcadomide is a CELMoD agent in development for the treatment of non-Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
- Golcadomide is a CELMoD (Cereblon E3 Ligase Modulator) that works in the treatment of B-cell malignancies by potently degrading the Ikaros and Aiolos transcription factors, resulting in antiproliferative, apoptotic, and immunomodulatory activity.
- The golcadomide development program includes the following studies:
- CC-99282-NHL-001 Phase 1/2 study evaluating golcadomide with rituximab in relapsed/refractory non-Hodgkin lymphoma.
- CC-220-DLBCL-001 Phase 1b study of golcadomide plus R-CHOP in previously untreated aggressive B-cell lymphoma.
- GOLSEEK-2 Phase 2 randomized, open-label study to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
- GOLSEEK-1 Phase 3 double-blind, randomized study comparing the efficacy and safety of golcadomide plus R-CHOP vs R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma.
Development timeline for golcadomide
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.